Distribution of ACAs by translocation partner and clinically relevant parameters
| . | n . | ACAs, n (%) . | ACAs type . | ||
|---|---|---|---|---|---|
| Numerical, n (%) . | Structural, n (%) . | Both, n (%) . | |||
| TP group | |||||
| 9p22 | 316 | 148 (47) | 84 (57)* | 40 (27)* | 24 (16)* |
| 10p12 | 96 | 48 (50) | 13 (27)* | 26 (54)* | 9 (19)* |
| 6q27 | 35 | 17 (49) | 8 (47)* | 7 (41)* | 2 (12)* |
| 19p13 | 30 | 10 (33) | 6 (60)* | 1 (10)* | 3 (30)* |
| 19p13.1 | 34 | 13 (38) | 5 (38)* | 4 (31)* | 4 (31)* |
| 19p13.3 | 25 | 13 (52) | 5 (38)* | 4 (31)* | 4 (31)* |
| 1q21 | 24 | 6 (25) | 2 (33)* | 3 (50)* | 1 (17)* |
| 4q21 | 13 | 8 (62) | 2 (25)* | 4 (50)* | 2 (25)* |
| 10p11.2 | 12 | 7 (58) | 0* | 5 (71)* | 2 (29)* |
| 17q21 | 12 | 3 (25) | 1 (33)* | 1 (33)* | 1 (33)* |
| other | 136 | 71 (52) | 14 (20)* | 35 (49)* | 22 (31)* |
| 733 | |||||
| Sex | |||||
| Male | 358 | 171 (48) | 78 (46) | 63 (37) | 30 (18) |
| Female | 375 | 173 (46) | 62 (36) | 67 (39) | 44 (25) |
| 733 | |||||
| Age, y | |||||
| < 2 | 344 | 143 (42) | 45 (31)† | 68 (48)† | 30 (21)† |
| 2-9 | 219 | 115 (53) | 57 (50)† | 35 (30)† | 23 (20)† |
| ≥ 10 | 170 | 86 (51) | 38 (44)† | 27 (31)† | 21 (24)† |
| 733 | |||||
| WBC, ×109/L | |||||
| < 20 | 339 | 175 (52) | 84 (49)† | 51 (29)† | 40 (23)† |
| 20-99 | 203 | 87 (43) | 28 (32)† | 40 (46)† | 19 (22)† |
| ≥ 100 | 171 | 73 (43) | 25 (34)† | 35 (48)† | 13 (18)† |
| 713 | |||||
| FAB | |||||
| M0 | 23 | 12 (52) | 6 (50) | 3 (25) | 3 (25) |
| M1 | 39 | 20 (51) | 9 (45) | 7 (35) | 4 (20) |
| M2 | 32 | 12 (38) | 7 (58) | 4 (33) | 1 (8) |
| M4 | 134 | 49 (37) | 21 (43) | 21 (43) | 7 (14) |
| M5 | 446 | 217 (49) | 88 (41) | 83 (38) | 46 (21) |
| M7 | 19 | 15 (79) | 7 (47) | 2 (13) | 6 (4) |
| n.d. | 7 | 5 (71) | 0 | 2 (40) | 3 (60) |
| 700 | |||||
| Overall | 344 (47) | 140 (41) | 130 (38) | 74 (22) | |
| . | n . | ACAs, n (%) . | ACAs type . | ||
|---|---|---|---|---|---|
| Numerical, n (%) . | Structural, n (%) . | Both, n (%) . | |||
| TP group | |||||
| 9p22 | 316 | 148 (47) | 84 (57)* | 40 (27)* | 24 (16)* |
| 10p12 | 96 | 48 (50) | 13 (27)* | 26 (54)* | 9 (19)* |
| 6q27 | 35 | 17 (49) | 8 (47)* | 7 (41)* | 2 (12)* |
| 19p13 | 30 | 10 (33) | 6 (60)* | 1 (10)* | 3 (30)* |
| 19p13.1 | 34 | 13 (38) | 5 (38)* | 4 (31)* | 4 (31)* |
| 19p13.3 | 25 | 13 (52) | 5 (38)* | 4 (31)* | 4 (31)* |
| 1q21 | 24 | 6 (25) | 2 (33)* | 3 (50)* | 1 (17)* |
| 4q21 | 13 | 8 (62) | 2 (25)* | 4 (50)* | 2 (25)* |
| 10p11.2 | 12 | 7 (58) | 0* | 5 (71)* | 2 (29)* |
| 17q21 | 12 | 3 (25) | 1 (33)* | 1 (33)* | 1 (33)* |
| other | 136 | 71 (52) | 14 (20)* | 35 (49)* | 22 (31)* |
| 733 | |||||
| Sex | |||||
| Male | 358 | 171 (48) | 78 (46) | 63 (37) | 30 (18) |
| Female | 375 | 173 (46) | 62 (36) | 67 (39) | 44 (25) |
| 733 | |||||
| Age, y | |||||
| < 2 | 344 | 143 (42) | 45 (31)† | 68 (48)† | 30 (21)† |
| 2-9 | 219 | 115 (53) | 57 (50)† | 35 (30)† | 23 (20)† |
| ≥ 10 | 170 | 86 (51) | 38 (44)† | 27 (31)† | 21 (24)† |
| 733 | |||||
| WBC, ×109/L | |||||
| < 20 | 339 | 175 (52) | 84 (49)† | 51 (29)† | 40 (23)† |
| 20-99 | 203 | 87 (43) | 28 (32)† | 40 (46)† | 19 (22)† |
| ≥ 100 | 171 | 73 (43) | 25 (34)† | 35 (48)† | 13 (18)† |
| 713 | |||||
| FAB | |||||
| M0 | 23 | 12 (52) | 6 (50) | 3 (25) | 3 (25) |
| M1 | 39 | 20 (51) | 9 (45) | 7 (35) | 4 (20) |
| M2 | 32 | 12 (38) | 7 (58) | 4 (33) | 1 (8) |
| M4 | 134 | 49 (37) | 21 (43) | 21 (43) | 7 (14) |
| M5 | 446 | 217 (49) | 88 (41) | 83 (38) | 46 (21) |
| M7 | 19 | 15 (79) | 7 (47) | 2 (13) | 6 (4) |
| n.d. | 7 | 5 (71) | 0 | 2 (40) | 3 (60) |
| 700 | |||||
| Overall | 344 (47) | 140 (41) | 130 (38) | 74 (22) | |
ACAs (%) indicates number of cases with additional aberrations and percentage within this group; Numerical (%), number of cases with only numerical additional aberrations and percentage of specific group (row); Structural (%), number of cases with only structural additional aberrations and percentage of specific group (row); Both (%), number of cases with both numerical and structural additional aberrations and percentage of specific group (row); and TP group, site of translocation on partner chromosome
ACA indicates additional cytogenetic aberrations; dx, diagnosis; FAB, French American British morphology classification subtype; n.d., not determined; TP, translocation partner; and WBC, white blood cell count.
Values significantly different at the P < .01 level (χ2).